Nucleic acid respiratory syncytial virus vaccines

FIELD OF INVENTION
The present invention is related to the field of Respiratory Syncytial Virus (RSV) vaccines and is particularly concerned with vaccines comprising nucleic acid sequences encoding the fusion (F) protein of RSV.
BACKGROUND OF INVENTION
Respiratory syncytial virus (RSV), a negative-strand RNA virus belonging to the Paramyxoviridae family of viruses, is the major viral pathogen responsible for bronchiolitis and pneumonia in infants and young children (ref. 1--Throughout this application, various references are referred to in parenthesis to more fully describe the state of the art to which this invention pertains. Full bibliographic information for each citation is found at the end of the specification, immediately preceding the claims. The disclosures of these references are hereby incorporated by reference into the present disclosure). Acute respiratory tract infections caused by RSV result in approximately 90,000 hospitalizations and 4,500 deaths per year in the United States (ref. 2). Medical care costs due to RSV infection are greater than $340 M annually in the United States alone (ref. 3). There is currently no licensed vaccine against RSV. The main approaches for developing an RSV vaccine have included inactivated virus, live-attenuated viruses and subunit vaccines.
The F protein of RSV is considered to be one of the most important protective antigens of the virus. There is a significant similarity (89% identity) in the amino acid sequences of the F proteins from RSV subgroups A and B (ref. 3) and anti-F antibodies can cross-neutralize viruses of both subgroups as well as protect immunized animals against infection with viruses from both subgroups (ref. 4). Furthermore, the F protein has been identified as a major target for RSV-specific cytotoxic T-lymphocytes in mice and humans (ref. 3 and ref. 5).
The use of RSV proteins as vaccines may have obstacles. Parenterally administered vaccine candidates have so far proven to be poorly immunogenic with regard to the induction of neutralizing antibodies in seronegative humans or chimpanzees. The serum antibody response induced by these antigens may be further diminished in the presence of passively acquired antibodies, such as the transplacentally acquired maternal antibodies which most young infants possess. A subunit vaccine candidate for RSV consisting of purified fusion glycoprotein from RSV infected cell cultures and purified by immunoaffinity or ion-exchange chromatography has been described (ref. 6). Parenteral immunization of seronegative or seropositive chimpanzees with this preparation was performed and three doses of 50 .mu.g were required in seronegative animals to induce an RSV serum neutralizing titre of approximately 1:50. Upon subsequent challenge of these animals with wild-type RSV, no effect of immunization on virus shedding or clinical disease could be detected in the upper respiratory tract. The effect of immunization with this vaccine on virus shedding in the lower respiratory tract was not investigated, although this is the site where the serum antibody induced by parenteral immunization may be expected to have its greatest effect. Safety and immunogenicity studies have been performed in a small number of seropositive individuals. The vaccine was found to be safe in seropositive children and in three seronegative children (all>2.4 years of age). The effects of immunization on lower respiratory tract disease could not be determined because of the small number of children immunized. One immunizing dose in seropositive children induced a 4-fold increase in virus neutralizing antibody titres in 40 to 60% of the vaccines. Thus, insufficient information is available from these small studies to evaluate the efficacy of this vaccine against RSV-induced disease. A further problem facing subunit RSV vaccines is the possibility that inoculation of seronegative subjects with immunogenic preparations might result in disease enhancement (sometimes referred to as immunopotentiation), similar to that seen in formalin inactivated RSV vaccines. In some studies, the immune response to immunization with RSV F protein or a synthetic RSV FG fusion protein resulted in a disease enhancement in rodents resembling that induced by a formalin-inactivated RSV vaccine. The association of immunization with disease enhancement using non-replicating antigens suggests caution in their use as vaccines in seronegative humans.
Live attenuated vaccines against disease caused by RSV may be promising for two main reasons. Firstly, infection by a live vaccine virus induces a balanced immune response comprising mucosal and serum antibodies and cytotoxic T-lymphocytes. Secondly, infection of infants with live attenuated vaccine candidates or naturally acquired wild-type virus is not associated with enhanced disease upon subsequent natural reinfection. It will be challenging to produce live attenuated vaccines that are immunogenic for younger infants who possess maternal virus-neutralizing antibodies and yet are attenuated for seronegative infants greater than or equal to 6 months of age. Attenuated live virus vaccines also have the risks of residual virulence and genetic instability.
Injection of plasmid DNA containing sequences encoding a foreign protein has been shown to result in expression of the foreign protein and the induction of antibody and cytotoxic T-lymphocyte responses to the antigen in a number of studies (see, for example, refs. 7, 8, 9). The use of plasmid DNA inoculation to express viral proteins for the purpose of immunization may offer several advantages over the strategies summarized above. Firstly, DNA encoding a viral antigen can be introduced in the presence of antibody to the virus itself, without loss of potency due to neutralization of virus by the antibodies. Secondly, the antigen expressed in vivo should exhibit a native conformation and, therefore, should induce an antibody response similar to that induced by the antigen present in the wild-type virus infection. In contrast, some processes used in purification of proteins can induce conformational changes which may result in the loss of immunogenicity of protective epitopes and possibly immunopotentiation. Thirdly, the expression of proteins from injected plasmid DNAs can be detected in vivo for a considerably longer period of time than that in virus-infected cells, and this has the theoretical advantage of prolonged cytotoxic T-cell induction and enhanced antibody responses. Fourthly, in vivo expression of antigen may provide protection without the need for an extrinsic adjuvant.
The ability to immunize against disease caused by RSV by administration of a DNA molecule encoding an RSV F protein was unknown before the present invention. In particular, the efficacy of immunization against RSV induced disease using a gene encoding a secreted form of the RSV F protein was unknown. Infection with RSV leads to serious disease. It would be useful and desirable to provide isolated genes encoding RSV F protein and vectors for in vivo administration for use in immunogenic preparations, including vaccines, for protection against disease caused by RSV and for the generation of diagnostic reagents and kits. In particular, it would be desirable to provide vaccines that are immunogenic and protective in humans, including seronegative infants, that do not cause disease enhancement (immunopotentiation).
SUMMARY OF INVENTION
The present invention relates to a method of immunizing a host against disease caused by respiratory syncytial virus, to nucleic acid molecules used therein, and to diagnostic procedures utilizing the nucleic acid molecules. In particular, the present invention is directed towards the provision of nucleic acid respiratory syncytial virus vaccines.
In accordance with one aspect of the invention, there is provided an immunogenic composition for in vivo administration to a host for the generation in the host of a protective immune response to RSV F protein, comprising a non-replicating vector comprising:
a first nucleotide sequence encoding an RSV F protein or a RSV F protein fragment that generates antibodies that specifically react with RSV F protein;
a promoter sequence operatively coupled to the first nucleotide sequence for expression of the RSV F protein, and
a second nucleotide sequence located adjacent the first nucleotide sequence to enhance the immunoprotective ability of the RSV F protein when expressed in vivo from the vector in a host; and
a pharmaceutically-acceptable carrier therefor.
The first nucleotide sequence may be that which encodes a full-length RSV F protein, as seen in FIG. 2 (SEQ ID No: 2). Alternatively, the first nucleotide sequence may be that which encodes an RSV F protein from which the transmembrane region is absent. The latter embodiment may be provided by a nucleotide sequence which encodes a full-length RSV F protein but contains a translational stop codon immediately upstream of the start of the transmembrane coding region, thereby preventing expression of a transmembrane region of the RSV F protein, as seen in FIG. 3 (SEQ. ID No. 4). The lack of expression of the transmembrane region results in a secreted form of the RSV F protein.
The second nucleotide sequence may comprise a pair of splice sites to prevent aberrant mRNA splicing, whereby substantially all transcribed mRNA encodes the RSV protein. Such second nucleotide sequence may be located between the first nucleotide sequence and the promoter sequence. Such second nucleotide sequence may be that of rabbit .beta.-globin intron II, as shown in FIG. 8 (SEQ ID No: 5).
A vector encoding the F protein and provided by this aspect of the invention may specifically be pXL2 or pXL4, as seen in FIGS. 5 or 7.
The promoter sequence may be an immediate early cytomegalovirus (CMV) promoter.
Certain of the vectors provided herein may be used to immunize a host against RSV infection or disease by in vivo expression of RSV F protein lacking a transmembrane region following administration of the vectors. In accordance with a further aspect of the present invention, therefore, there is provided a method of immunizing a host against disease caused by infection with respiratory syncytial virus, which comprises administering to the host an effective amount a of non-replicating vector comprising a first nucleotide sequence encoding an RSV F protein or a RSV F protein fragment that generates antibodies that specifically react with RSV F protein and a promoter sequence operatively coupled to the first nucleotide sequence for expression of the RSV F protein in the host, which may be a human. The promoter may be an immediate early cytomegalovirus promoter.
The nucleotide sequence may encode a truncated RSV F protein lacking the transmembrane region may be that as described above.
The vector may contain a second nucleotide sequence located adjacent a first nucleotide sequence and effective to enhance the immunoprotective ability of the RSV F protein expressed by the first nucleotide sequence may be used to immunize a host. Specific non-replicating vectors which may be used in this aspect of the invention are those identified as plasmid vectors pXL2 and pXL4 in FIGS. 5 and 7.
The present invention also includes a novel method of using a gene encoding an RSV F protein or a RSV F protein fragment that generates antibodies that specifically react with RSV F protein to protect a host against disease caused by infection with respiratory syncytial virus, which comprises:
isolating the gene;
operatively linking the gene to at least one control sequence to produce a non-replicating vector, said control sequence directing expression of the RSV F protein when said vector is introduced into a host to produce an immune response to the RSV F protein, and introducing the vector into the host.
The procedure provided in accordance with this aspect of the invention may further include the step of:
operatively linking the gene to an immunoprotection enhancing sequence to produce an enhanced immunoprotection by the RSV F protein in the host, preferably by introducing the immunoprotection enhancing sequence between the control sequence and the gene.
In addition, the present invention includes a method of producing a vaccine for protection of a host against disease caused by infection with respiratory syncytial virus, which comprises:
isolating a first nucleotide sequence encoding an RSV F protein or a RSV F protein fragment that generates antibodies that specifically react with RSV F protein;
operatively linking the first nucleotide sequence to at least one control sequence to produce a non-replicating vector, the control sequence directing expression of the RSV F protein when introduced into a host to produce an immune response to the RSV F protein when expressed in vivo from the vector in a host, and
formulating the vector as a vaccine for in vivo administration.
The first nucleotide sequence further may be operatively linked to a second nucleotide sequence to enhance the immunoprotective ability of the RSV F protein when expressed in vivo from the vector in a host. The vector may be a plasmid vector selected from pXL1, pXL2 and pXL4. The invention further includes a vaccine for administration to a host, including a human host, produced by this method as well as immunogenic compositions comprising an immunoeffective amount of the vectors described herein.
As noted previously, the vectors provided herein are useful in diagnostic applications. In a further aspect of the invention, therefore, there is provided a method of determining the presence of an RSV F protein in a sample, comprising the steps of:
(a) immunizing a host with a non-replicating vector comprising a first nucleotide sequence encoding an RSV F protein or a RSV F protein fragment that generates antibodies that specifically react with RSV F protein and a promoter sequence operatively coupled to the first nucleotide sequence for expression of the RSV F protein in the host to produce antibodies specific for the RSV F protein;
(b) isolating the RSV F protein specific antibodies;
(c) contacting the sample with the isolated antibodies to produce complexes comprising any RSV F protein present in the sample and the RSV F protein-specific antibodies; and
(d) determining production of the complexes.
The non-replicating vector employed to elicit the antibodies may be a plasmid vector which is pXL1, pXL2, pXL3 or pXL4.
The invention also includes a diagnostic kit for detecting the presence of an RSV F protein in a sample, comprising:
(a) a non-replicating vector comprising a first nucleotide sequence encoding an RSV F protein or a RSV F protein fragment that generates antibodies that specifically react with RSV F protein and a promoter sequence operatively coupled to said first nucleotide sequence for expression of said RSV F protein in a host immunized therewith to produce antibodies specific for the RSV F protein;
(b) isolation means to isolate said RSV F protein specific antibodies;
(c) contacting means to contact the isolated RSV F specific antibodies with the sample to produce a complex comprising any RSV F protein present in the sample and RSV F protein specific antibodies; and
(d) identifying means to determine production of the complex.
The present invention is further directed to immunization wherein the polynucleotide is an RNA molecule which codes for an RSV F protein or a RSV F protein fragment that generates antibodies that specifically react with RSV F protein.
The present invention is further directed to a method for producing RSV F protein specific polyclonal antibodies comprising the use of the immunization method described herein, and further comprising the step of isolating the RSV F protein specific polyclonal antibodies from the immunized animal.
The present invention is also directed to a method for producing monoclonal antibodies specific for an F protein of RSV, comprising the steps of:
(a) constructing a non-replicating vector comprising a first nucleotide sequence encoding a RSV F protein and a promoter sequence operatively coupled to said first nucleotide sequence for expression of said RSV F protein; and, optionally,
a second nucleotide sequence located adjacent said first nucleotide sequence to enhance the immunoprotective ability of said RSV F protein when expressed in vivo from said vector in a host.
(b) administering the vector to at least one mouse to produce at least one immunized mouse;
(c) removing B-lymphocytes from the at least one immunized mouse;
(d) fusing the B-lymphocytes from the at least one immunized mouse with myeloma cells, thereby producing hybridomas;
(e) cloning the hybridomas;
(f) selecting clones which produce anti-F protein antibody;
(g) culturing the anti-F protein antibody-producing clones; and
(h) isolating anti-F protein monoclonal antibodies.
In this application, the term "RSV F protein" is used to define (1) a full-length RSV F protein, such proteins having variations in their amino acid sequences including those naturally occurring in various strains of RSV, (2) a secreted form of RSV F protein lacking a transmembrane region, and (3) functional analogs of the RSV F protein. In this application, a first protein is a "functional analog" of a second protein if the first protein is immunologically related to and/or has the same function as the second protein. The functional analog may be, for example, a fragment of the protein or a substitution, addition or deletion mutant thereof. Included are RSV F protein fragments that generate antibodies that specifically react with RSV F protein.

BRIEF DESCRIPTION OF THE FIGURES
The present invention will be further understood from the following General Description and Examples with reference to the Figures in which:
FIG. 1 illustrates a restriction map of the gene encoding the F protein of Respiratory Syncytial Virus;
FIGS. 2A, 2B, 2C, 2D and 2E show the nucleotide sequence of the gene encoding the membrane attached form of the F protein of Respiratory Syncytial Virus (SEQ ID No: 1) as well as the amino acid sequence of the RSV F protein encoded thereby (SEQ ID No: 2);
FIGS. 3A, 3B, 3C and 3D show the nucleotide sequence of the gene encoding the secreted form of the RSV F protein lacking the transmembrane region (SEQ ID No: 3) as well as the amino acid sequence of the truncated RSV F protein lacking the transmembrane region encoded thereby (SEQ ID No: 4);
FIGS. 4A, 4B, 4C and 4D show the construction of plasmid pXL1 containing the gene encoding a secreted form of the RSV F protein lacking the transmembrane region;
FIGS. 5A, 5B, 5C and 5D show the construction of plasmid pXL2 containing a gene encoding a secreted form of the RSV F protein lacking the transmembrane region and containing the rabbit .beta.-globin Intron II sequence;
FIGS. 6A, 6B, 6C and 6D show the construction of plasmid pXL3 containing the gene encoding a full length membrane attached form of the RSV F protein;
FIGS. 7A, 7B, 7C and 7D show the construction of plasmid pXL4 containing a gene encoding a membrane attached form of the RSV F protein and containing the rabbit .beta.-globin Intron II sequence; and
FIG. 8 shows the nucleotide sequence for the rabbit .beta.-globin Intron II sequence (SEQ ID No. 5).

GENERAL DESCRIPTION OF INVENTION
As described above, the present invention relates generally to polynucleotide, including DNA, immunization to obtain protection against infection by respiratory syncytial virus (RSV) and to diagnostic procedures using particular vectors. In the present invention, several recombinant vectors were constructed to contain a nucleotide sequence encoding an RSV F protein.
The nucleotide sequence of the full length RSV F gene is shown in FIG. 2 (SEQ ID No: 1). Certain constructs provided herein include the nucleotide sequence encoding the full-length RSV F (SEQ ID No: 2) protein while others include an RSV F gene modified by insertion of termination codons immediately upstream of the transmembrane coding region (see FIG. 3, SEQ ID No: 3), to prevent expression of the transmembrane portion of the protein and to produce a secreted or truncated RSV F protein lacking a transmembrane region (SEQ ID No. 4).
The nucleotide sequence encoding the RSV F protein is operatively coupled to a promoter sequence for expression of the encoded RSV F protein. The promoter sequence may be the immediately early cytomegalovirus (CMV) promoter. This promoter is described in ref. 13. Any other convenient promoter may be used, including constitutive promoters, such as, Rous Sarcoma Virus LTRs, and inducible promoters, such as metallothionine promoter, and tissue specific promoters.
The vectors provided herein, when administered to an animal, effect in vivo RSV F protein expression, as demonstrated by an antibody response in the animal to which it is administered. Such antibodies may be used herein in the detection of RSV protein in a sample, as described in more detail below. When the encoded RSV F protein is in the form of an RSV F protein from which the transmembrane region is absent, such as plasmid pXL1 (FIG. 4), the administration of the vector conferred protection in mice and cotton rats to challenge by live RSV virus neutralizing antibody and cell mediated immune responses and an absence of immunopotentiation in immunized animals, as seen from the Examples below.
The recombinant vector also may include a second nucleotide sequence located adjacent the RSV F protein encoding nucleotide sequence to enhance the immunoprotective ability of the RSV F protein when expressed in vivo in a host. Such enhancement may be provided by increased in vivo expression, for example, by increased mRNA stability, enhanced transcription and/or translation. This additional sequence preferably is located between the promoter sequence and the RSV F protein-encoding sequence.
This enhancement sequence may comprise a pair of splice sites to prevent aberrant mRNA splicing during transcription and translation so that substantially all transcribed mRNA encodes an RSV F protein. Specifically, rabbit .beta.-globin Intron II sequence shown in FIG. 7 (SEQ ID No: 5) may provide such splice sites, as also described in ref. 15.
The constructs containing the Intron II sequence, CMV promoter and nucleotide sequence coding for the truncated RSV F protein lacking a transmembrane region, i.e. plasmid pXL2 (FIG. 5), induced complete protection in mice against challenge with live RSV, as seen in the Examples below. In addition, the constructs containing the Intron II sequence, CMV promoter and nucleotide sequence coding for the full-length RSV F protein, i.e. plasmid pXL4 (FIG. 7), also conferred protection in mice to challenge with live RSV, as seen from the Examples below.
The vector provided herein may also comprise a third nucleotide sequence encoding a further antigen from RSV, an antigen from at least one other pathogen or at least one immunomodulating agent, such as cytokine. Such vector may contain said third nucleotide sequence in a chimeric or a bicistronic structure. Alternatively, vectors containing the third nucleotide sequence may be separately constructed and coadministered to a host, with the nucleic acid molecule provided herein.
The vector may further comprise a nucleotide sequence encoding a heterologous signal peptide, such as human tissue plasminogen activator (TPA), in place of the endogenous signal peptide.
It is clearly apparent to one skilled in the art, that the various embodiments of the present invention have many applications in the fields of vaccination, diagnosis and treatment of RSV infections. A further non-limiting discussion of such uses is further presented below.
1. Vaccine Preparation and Use
Immunogenic compositions, suitable to be used as vaccines, may be prepared from the RSV F genes and vectors as disclosed herein. The vaccine elicits an immune response in a subject which includes the production of anti-F antibodies. Immunogenic compositions, including vaccines, containing the nucleic acid may be prepared as injectables, in physiologically-acceptable liquid solutions or emulsions for polynucleotide administration. The nucleic acid may be associated with liposomes, such as lecithin liposomes or other liposomes known in the art, as a nucleic acid liposome (for example, as described in WO 9324640, ref. 17) or the nucleic acid may be associated with an adjuvant, as described in more detail below. Liposomes comprising cationic lipids interact spontaneously and rapidly with polyanions such as DNA and RNA, resulting in liposome/nucleic acid complexes that capture up to 100% of the polynucleotide. In addition, the polycationic complexes fuse with cell membranes, resulting in an intracellular delivery of polynucleotide that bypasses the degradative enzymes of the lysosomal compartment. Published PCT application WO 94/27435 describes compositions for genetic immunization comprising cationic lipids and polynucleotides. Agents which assist in the cellular uptake of nucleic acid, such as calcium ions, viral proteins and other transfection facilitating agents, may advantageously be used.
Polynucleotide immunogenic preparations may also be formulated as microcapsules, including biodegradable time-release particles. Thus, U.S. Pat. No. 5,151,264 describes a particulate carrier of a phospholipid/glycolipid/polysaccharide nature that has been termed Bio Vecteurs Supra Moleculaires (BVSM). The particulate carriers are intended to transport a variety of molecules having biological activity in one of the layers thereof.
U.S. Pat. No. 5,075,109 describes encapsulation of the antigens trinitrophenylated keyhole limpet hemocyanin and staphylococcal enterotoxin B in 50:50 poly (DL-lactideco-glycolide). Other polymers for encapsulation are suggested, such as poly(glycolide), poly(DL-lactide-co-glycolide), copolyoxalates, polycaprolactone, poly(lactide-co-caprolactone), poly(esteramides), polyorthoesters and poly(8-hydroxybutyric acid), and polyanhydrides.
Published PCT application WO 91/06282 describes a delivery vehicle comprising a plurality of bioadhesive microspheres and antigens. The microspheres being of starch, gelatin, dextran, collagen or albumin. This delivery vehicle is particularly intended for the uptake of vaccine across the nasal mucosa. The delivery vehicle may additionally contain an absorption enhancer.
The RSV F genes and vectors may be mixed with pharmaceutically acceptable excipients which are compatible therewith. Such excipients may include, water, saline, dextrose, glycerol, ethanol, and combinations thereof. The immunogenic compositions and vaccines may further contain auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, or adjuvants to enhance the effectiveness thereof. Immunogenic compositions and vaccines may be administered parenterally, by injection subcutaneously, intravenously, intradermally or intramuscularly, possibly following pretreatment of the injection site with a local anesthetic. Alternatively, the immunogenic compositions formed according to the present invention, may be formulated and delivered in a manner to evoke an immune response at mucosal surfaces. Thus, the immunogenic composition may be administered to mucosal surfaces by, for example, the nasal or oral (intragastric) routes. Alternatively, other modes of administration including suppositories and oral formulations may be desirable. For suppositories, binders and carriers may include, for example, polyalkalene glycols or triglycerides. Oral formulations may include normally employed incipients, such as, for example, pharmaceutical grades of saccharine, cellulose and magnesium carbonate.
The immunogenic preparations and vaccines are administered in a manner compatible with the dosage formulation, and in such amount as will be therapeutically effective, protective and immunogenic. The quantity to be administered depends on the subject to be treated, including, for example, the capacity of the individual's immune system to synthesize the RSV F protein and antibodies thereto, and if needed, to produce a cell-mediated immune response. Precise amounts of active ingredient required to be administered depend on the judgment of the practitioner. However, suitable dosage ranges are readily determinable by one skilled in the art and may be of the order of about 1 .mu.g to about 1 mg of the RSV F genes and vectors. Suitable regimes for initial administration and booster doses are also variable, but may include an initial administration followed by subsequent administrations. The dosage may also depend on the route of administration and will vary according to the size of the host. A vaccine which protects against only one pathogen is a monovalent vaccine. Vaccines which contain antigenic material of several pathogens are combined vaccines and also belong to the present invention. Such combined vaccines contain, for example, material from various pathogens or from various strains of the same pathogen, or from combinations of various pathogens.
Immunogenicity can be significantly improved if the vectors are co-administered with adjuvants, commonly used as 0.05 to 0.1 percent solution in phosphate-buffered saline. Adjuvants enhance the immunogenicity of an antigen but are not necessarily immunogenic themselves. Adjuvants may act by retaining the antigen locally near the site of administration to produce a depot effect facilitating a slow, sustained release of antigen to cells of the immune system. Adjuvants can also attract cells of the immune system to an antigen depot and stimulate such cells to elicit immune responses.
Immunostimulatory agents or adjuvants have been used for many years to improve the host immune responses to, for example, vaccines. Thus, adjuvants have been identified that enhance the immune response to antigens. Some of these adjuvants are toxic, however, and can cause undesirable side-effects, making them unsuitable for use in humans and many animals. Indeed, only aluminum hydroxide and aluminum phosphate (collectively commonly referred to as alum) are routinely used as adjuvants in human and veterinary vaccines.
A wide range of extrinsic adjuvants and other immunomodulating material can provoke potent immune responses to antigens. These include saponins complexed to membrane protein antigens to produce immune stimulating complexes (ISCOMS), pluronic polymers with mineral oil, killed mycobacteria in mineral oil, Freund's complete adjuvant, bacterial products, such as muramyl dipeptide (MDP) and lipopolysaccharide (LPS), as well as monophoryl lipid A, QS 21 and polyphosphazene.
In particular embodiments of the present invention, the vector comprising a first nucleotide sequence encoding an F protein of RSV may be delivered in conjunction with a targeting molecule to target the vector to selected cells including cells of the immune system.
The polynucleotide may be delivered to the host by a variety of procedures, for example, Tang et al. (ref. 10) disclosed that introduction of gold microprojectiles coated with DNA encoding bovine growth hormone (BGH) into the skin of mice resulted in production of anti-BGH antibodies in the mice, while Furth et al. (ref. 11) showed that a jet injector could be used to transfect skin, muscle, fat and mammary tissues of living animals.
2. Immunoassays
The RSV F genes and vectors of the present invention are useful as immunogens for the generation of anti-F antibodies for use in immunoassays, including enzyme-linked immunosorbent assays (ELISA), RIAs and other non-enzyme linked antibody binding assays or procedures known in the art. In ELISA assays, the vector first is administered to a host to generate antibodies specific to the RSV F protein. These RSV F-specific antibodies are immobilized onto a selected surface, for example, a surface capable of binding the antibodies, such as the wells of a polystyrene microtiter plate. After washing to remove incompletely adsorbed antibodies, a nonspecific protein such as a solution of bovine serum albumin (BSA) that is known to be antigenically neutral with regard to the test sample may be bound to the selected surface. This allows for blocking of nonspecific adsorption sites on the immobilizing surface and thus reduces the background caused by nonspecific bindings of antisera onto the surface.
The immobilizing surface is then contacted with a sample, such as clinical or biological materials, to be tested in a manner conducive to immune complex (antigen/antibody) formation. This procedure may include diluting the sample with diluents, such as solutions of BSA, bovine gamma globulin (BGG) and/or phosphate buffered saline (PBS)/Tween. The sample is then allowed to incubate for from about 2 to 4 hours, at temperatures such as of the order of about 20.degree. to 37.degree. C.
Following incubation, the sample-contacted surface is washed to remove non-immunocomplexed material. The washing procedure may include washing with a solution, such as PBS/Tween or a borate buffer. Following formation of specific immunocomplexes between the test sample and the bound RSV F specific antibodies, and subsequent washing, the occurrence, and even amount, of immunocomplex formation may be determined.
BIOLOGICAL MATERIALS
Certain plasmids that contain the gene encoding RSV F protein and referred to herein have been deposited with the America Type Culture Collection (ATCC) located at 12301 Parklawn Drive, Rockville, Md., 20852, U.S.A., pursuant to the Budapest Treaty and prior to the filing of this application.
Samples of the deposited plasmids will become available to the public upon grant of a patent based upon this United States patent application and all restrictions on access to the deposits will be removed at that time. The invention described and claimed herein is not to be limited in scope by plasmids deposited, since the deposited embodiment is intended only as an illustration of the invention. Any equivalent or similar plasmids that encode similar or equivalent antigens as described in this application are within the scope of the invention.
______________________________________Plasmid ATCC Designation Date Deposited______________________________________pXL1 97167 May 30, 1995pXL2 97168 May 30, 1995PXL3 97169 May 30, 1995pXL4 97170 May 30, 1995______________________________________
EXAMPLES
The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific Examples. These Examples are described solely for purposes of illustration and are not intended to limit the scope of the invention. Changes in form and substitution of equivalents are contemplated as circumstances may suggest or render expedient. Although specific terms have been employed herein, such terms are intended in a descriptive sense and not for purposes of limitations.
Methods of molecular genetics, protein biochemistry, and immunology used but not explicitly described in this disclosure and these Examples are amply reported in the scientific literature and are well within the ability of those skilled in the art.
Example 1
This Example describes the construction of vectors containing the RSV F gene.
FIG. 1 shows a restriction map of the gene encoding the F protein of Respiratory Syncytial Virus and FIG. 2 shows the nucleotide sequence of the gene encoding the full-length RSV F protein (SEQ ID No: 1) and the deduced amino acid sequence (SEQ ID No: 2). FIG. 3 shows the gene encoding the secreted RSV F protein (SEQ ID No: 3) and the deduced amino acid sequence (SEQ ID No: 4).
A set of four plasmid DNA constructs were made (as shown schematically in FIGS. 4 to 7) in which cDNA encoding the RSV-F was subcloned downstream of the immediate-early promoter, enhancer and intron A sequences of human cytomegalovirus (CMV) and upstream of the bovine growth hormone (BGH) poly-A site. The 1.6 Kb Sspl-PstI fragment containing the promoter, enhancer and intron A sequences of CMV Towne strain were initially derived from plasmid pRL43a obtained from Dr. G. S. Hayward of Johns Hopkins University (ref. 20) and subcloned between EcoRV and PstI sites of pBluescript 11 SK +/- (Stratagene). For the construction of plasmids expressing the secretory form of the F protein (pXL1 and pXL2 in FIGS. 4 and 5), the 1.6 Kb EcoRI-BamHI fragment containing the truncated form of the F cDNA originally cloned from a clinical isolate belonging to subgroup A was excised from PRSVF (ref. 18 and WO 93/14207) and subcloned between EcoRI and BamHI sites of pSG5 (Strategene, ref. 14). Either the 1.6 kb EcoRI-BamHI fragment or the 2.2 kb ClaI-BamHI fragment was then excised from the pSG5 construct, filled-in with Klenow and subcloned at the SmaI site of the pBluescript II SK +/- construct containing the promoter and intron A sequences. The 0.6 kb ClaI-EcoRI fragment derived from pSG5 contained the intron II sequences from rabbit .beta.-globin. Subsequently, the plasmids were digested with HindIII, filled-in with Klenow, and digested with XbaI to yield either a 3.2 or a 3.8 Kb fragment. These fragments were used to replace the 0.8 kb NruI-XbaI fragment containing the CMV promoter in pRc/CMV (Invitrogen), resulting in the final pXL1 and pXL2 constructs, respectively.
For the construction of plasmids expressing the full-length F protein (pXL3 and pXL4--FIGS. 6 and 7), the full length RSV F cDNA was excised as a 1.9 kb EcoRI fragment from a recombinant pBluescript M13-SK (Stratagene) containing the insert (ref. 18 and WO 93/14207) and subcloned at the EcoRI site of pSG5 (Stratagene). Either the 1.9 Kb EcoRI fragment or the 2.5 Kb ClaI-BamHI fragment was then excised from the pSG5 construct, filled-in with Klenow and subcloned at the SmaI site of the pBluescript II SK +/- construct containing the promoter and intron A sequences. The rest of the construction for pXL3 and pXL4 was identical to that for pXL1 and pXL2, as described above. Therefore, except for the CMV promoter and intron A sequences, the rest of the vector components in pXL1-4 were derived from plasmid pRc/CMV. Plasmids pXL1 and pXL2 were made to express a truncated/secretory form of the F protein which carried stop codons resulting in a C-terminal deletion of 48 amino acids including the transmembrane (TM) and the C-terminal cytosolic tail as compared to the intact molecule. In contrast, pXL3 and pXL4 were made to express the intact membrane-attached form of the RSV F molecule containing the TM and the cytosolic C-terminal tail. The rationale for the presence of the intron II sequences in pXL2 and pXL4 was that this intron was reported to mediate the correct splicing of RNAs. Since mRNA for the RSV-F has been suspected to have a tendency towards aberrant splicing, the presence of the intron II sequences might help to overcome this. All four plasmid constructs were confirmed by DNA sequencing analysis.
Plasmid DNA was purified using plasmid mega kits from Qiagen (Chatsworth, Calif., USA) according to the manufacturer's instructions.
Example 2
This Example describes the immunization of mice. Mice are susceptible to infection by RSV as described in ref. 16.
For intramuscular (i.m) immunization, the anterior tibialis anterior muscles of groups of 9 BALB/c mice (male, 6-8 week old) (Jackson Lab., Bar Harbor, Me., USA) were bilaterally injected with 2.times.50 .mu.g (1 .mu.g/.mu.L in PBS) of pXL1-4, respectively. Five days prior to DNA injection, the muscles were treated with 2.times.50 .mu.L (10 .mu.M in PBS) of cardiotoxin (Latoxan, France). Pretreatment of the muscles with cardiotoxin has been reported to increase DNA uptake and to enhance the subsequent immune responses by the intramuscular route (ref. 24). These animals were similarly boosted a month later. Mice in the control group were immunized with a placebo plasmid containing identical vector backbone sequences without the RSV F gene according to the same schedule. For intradermal (i.d.) immunization, 100 .mu.g of pXL2 (2 .mu.g/.mu.L in PBS) were injected into the skin 1-2 cm distal from the tall base. The animals were similarly boosted a month later.
Seventy-five days after the second immunization, mice were challenged intranasally with 10.sup.5.4 plaque forming units (pfu) of mouse-adapted RSV, A2 subtype (obtained from Dr. P. Wyde, Baylor College of Medicine, Houston, Tex., USA). Lungs were aseptically removed 4 days later, weighed and homogenized in 2 mL of complete culture medium. The number of pfu in lung homogenates was determined in duplicates as previously described (ref. 19) using vaccine quality Vero cells. These data were subjected to statistic analysis using SigmaStat (Jandel Scientific Software, Guelph, Ont. Canada).
Sera obtained from immunized mice were analyzed for anti-RSV F antibody titres (IgG, IgG1 and IgG2a, respectively) by enzyme-linked immunosorbent assay (ELISA) and for RSV-specific plaque-reduction titres. ELISA were performed using 96-well plates coated with immunoaffinity purified RSV F protein (50 ng/mL) and 2-fold serial dilutions of immune sera. A goat anti-mouse IgG antibody conjugated to alkaline phosphatase (Jackson ImmunoRes., Mississauga, Ont., Canada) was used as secondary antibody. For the measurement of IgG1 and IgG2a antibody titres, the secondary antibodies used were monospecific sheep anti-mouse IgG1 (Serotec, Toronto, Ont., Canada) and rat anti-mouse IgG2a (Zymed, San Francisco, Calif., USA) antibodies conjugated to alkaline phosphatase, respectively. Plaque reduction titres were determined according to Prince et al (ref. 19) using vaccine quality Vero cells. Four-fold serial dilutions of immune sera were incubated with 50 pfu of RSV, Long strain (ATCC) in culture medium at 37.degree. C. for 1 hr in the presence of 5% CO.sub.2. Vero cells were then infected with the mixture. Plaques were fixed with 80% methanol and developed 5 days later using a mouse anti-RSV-F monoclonal IgG1 antibody and donkey antimouse IgG antibody conjugated to peroxidase (Jackson ImmunoRes., Mississauga, Ont. Canada). The RSV-specific plaque reduction titre was defined as the dilution of serum sample yielding 60% reduction in the number of plaques. Both ELISA and plaque reduction assays were performed in duplicates and data are expressed as the means of two determinations. These data were subjected to statistic analysis using SigmaStat (Jandel Scientific Software, Guelph, Ont. Canada).
To examine the induction of RSV-specific CTL following DNA immunization, spleens from 2 immunized mice were removed to prepare single cell suspensions which were pooled. Splenocytes were incubated at 2.5.times.10.sup.6 cells/mL in complete RPMI medium containing 10 U/mL murine interleukin 2 (IL-2) with .gamma.-irradiated (3,000 rads) syngeneic splenocytes (2.5.times.10.sup.6 cells/mL) infected with 1 TCID.sub.50 /cell RSV (Long strain) for 2 hr. The source of murine IL-2 was supernatant of a mouse cell line constitutively secreting a high level of IL-2 obtained from Dr. H. Karasuyama of Basel Institute for Immunology (ref. 20). CTL activity was tested 5 days following the in vitro re-stimulation in a standard 4 hr chromium release assay. Target cells were 5 .sup.51 Cr-labelled uninfected BALB/c fibroblasts (BC cells) and persistently RSV-infected BCH14 fibroblasts, respectively. Washed responder cells were incubated with 2.times.10.sup.3 target cells at varying effector to target ratios in 200 .mu.L in 96-well V-bottomed tissue-culture plates for 4 hr at 37.degree. C. Spontaneous and total chromium releases were determined by incubating target cells with either medium or 2.5% Triton-X 100 in the absence of responder lymphocytes. Percentage specific chromium release was calculated as (counts-spontaneous counts)/(total counts-spontaneous counts).times.100. Tests were performed in triplicates and data are expressed as the means of three determinations. For antibody blocking studies in CTL assays, the effector cells were incubated for 1 hr with 10 .mu.g/ml final of purified mAb to CD4 (GK1.5) (ref. 21) or mAb against murine CD8 (53-6.7) (ref. 22) before adding chromium labelled BC or BCH4 cells. To determine the effect of anti-class I MHC antibodies on CTL killing, the chromium labelled target cells BC or BCH4 were incubated with 20 .mu.L of culture supernate of hybridoma that secretes a mAb that recognizes K.sup.d and D.sup.d of class I MHC (34-1-2S) (ref. 23) prior to the addition of effector cells.
Example 3
This Example describes the immunogenicity and protection by polynucleotide immunization by the intramuscular route.
To characterize the antibody responses following i.m. DNA administration, immune sera were analyzed for anti-RSV F IgG antibody titre by ELISA and for RSV-specific plaque reduction titre, respectively. All four plasmid constructs were found to be immunogenic. Sera obtained from mice immunized with pXL1-4 demonstrated significant anti-RSV F IgG titres and RSV-specific plaque reduction titres as compared to the placebo group (Table 1 below) (P<0.0061 and <0.0001, respectively, Mann-Whitney Test). However, there is no significant difference in either anti-RSV F IgG titre or RSV-specific plaque reduction titre among mice immunized with either pXL1, pXL2, pXL3 or pXL4.
To evaluate the protective ability of pXL1-4 against primary RSV infection of the lower respiratory tract, immunized mice were challenged intranasally with mouse-adapted RSV and viral lung titres post challenge were assessed. All four plasmid constructs were found to protect animals against RSV infection. A significant reduction in the viral lung titre was observed in mice immunized with pXL1-4 as compared to the placebo group (P<0.0001, Mann-Whitney Test). However, varying degrees of protection were observed depending on the plasmid. In particular, PXL1 was more protective than pXL3 (P=0.00109, Mann-Whitney Test), and pXL4 more than pXL3 (P=0.00125), whereas only pXL2 induced complete protection. This conclusion was confirmed by another analysis with number of fully protected mice as end point (Fisher Exact Test). Constructs pXL1, pXL2 or pXL4 conferred a higher degree of protection than pXL3 (P<0.004, Fisher Exact Test) which was not more effective than placebo. Only pXL2 conferred full protection in all immunized mice.
The above statistical analysis revealed that PXL1 conferred more significant protection than pXL3. The former expresses the truncated and secretory form and the latter the intact membrane anchored form of the RSV F protein. Furthermore, pXL4 was shown to be more protective than pXL3. The difference between these two constructs is the presence of the intron II sequence in pXL4. Construct pXL2 which expresses the secretory form of the RSV-F in the context of the intron II sequence was the only plasmid that confers complete protection in all immunized mice.
Example 4
This Example describes the influence of the route of administration of pXL2 on its immunogenicity and protective ability.
The i.m. and i.d. routes of DNA administration were compared for immunogenicity in terms of anti-RSV F antibody titres and RSV-specific plaque reduction titres. Analyses of the immune sera (Table 2 below) revealed that the i.d. route of DNA administration was as immunogenic as the i.m. route as judged by anti-RSV F IgG and IgG1 antibody responses as well as RSV-specific plaque reduction titres. However, only the i.m. route induced significant anti-RSV F IgG2a antibody responses, whereas the IgG2a isotype titre was negligible when the i.d. route was used. The i.m. and i.d. routes were also compared with respect to the induction of RSV-specific CTL. Significant RSV-specific CTL activity was detected in mice immunized intramuscularly. In contrast, the cellular response was significantly lower in mice inoculated intradermally (Table 3 below). In spite of these differences, protection against primary RSV infection of the lower respiratory tract was observed in both groups of mice immunized via either route (Table 4 below). The CTL induced by RSV-F DNA are classical CD8+ class I restricted CTL. The target cells, BCH4 fibroblasts express class I MHC only and do not express class II MHC. Further, prior incubation of BCH4 target cells with anti class-I MHC antibodies significantly blocked the lytic activity of RSV-F DNA induced CTL line. While anti-CD8 antibody could partially block lysis of BCH4 cells, antibody to CD4 molecule had no effect at all (Table 5 below). Lack of total blocking by mAb to CD8 could either be due to CTL being CD8 independent (meaning that even though they are CD8+ CTL, their TCR has enough affinity for class I MHC+peptide and it does not require CD8 interaction with the alpha 3 of class I MHC) or the amount of antibody used in these experiments was limiting. There was no detectable lysis of YAC-1 (NK sensitive target) cells (data not shown).
Example 5
This Example describes immunization studies in cotton rats using pXL2.
The immune response of cotton rats to DNA immunization was analyzed by the protocol shown in Table 6 below. On day -5, 40 cotton rats were randomly selected and divided into 8 groups of 5. Cotton rats in groups 1 and 7 were inoculated intramuscularly (i.m.) into the tiberlia anteria (TA) muscles bilaterally with cardiotoxin (1.0 .mu.M). On day -1, the cotton rats in group 8 were inoculated in the TA muscles with bupivacaine (0.25%). On day 0, several animals in each group were bled to determine levels of RSV-specific antibodies in the serum of the test animals prior to administration of vaccines. All of the animals were then inoculated i.m. or intradermally (i.d.) with 200 .mu.g of plasmid DNA, placebo (non-RSV-specific DNA), 100 median cotton rat infectious doses (CRID50; positive control) of RSV, or of formalin inactivated RSV prepared in Hep-2 tissue culture cells and adjuvanted in alum. Forty-four days later the cotton rats in groups 1 & 7 were reinoculated with cardiotoxin in the TA muscles. Four days later (48 days after priming with vaccine), the animals in group 8 were reinoculated with bupivacains in the TA muscle of the right leg. The next day, (seven weeks after priming with vaccine) all of the animals were bled and all, except those in the group given live RSV, were boosted with the same material and doses used on day 0. 29 days later, each cotton rat was bled and then challenged intranasally (i.n.) with 100 CRID50 RSV A2 grown in Hep-2 tissue culture cells. Four days after this virus challenge (day +88) all of the cotton rats were killed and their lungs removed. One lobe from each set of lungs was fixed in formalin and then processed for histologic evaluation of pulmonary histopathology. The remaining lobes of lung will be assessed for the presence and levels of RSV. Each of the sera collected on days 0, 49 and 78 were tested for RSV-neutralizing activity, anti-RSV fusion activity and RSV-specific ELISA antibody.
The RSV neutralizing titres on day +49 and +78 are shown in Tables 7(a) below and 7(b) below respectively. As can be seen from the results shown in Table 7(a), on day +49 the animals immunized with live RSV and DNA immunization had substantial RSV serum neutralizing titres. The animals immunized with formalin-inactivated RSV had a neutralizing titre equivalent to the placebo group on day +49 but following boosting titres by day +78 had reached 5.8 (log.sub.10 /0.05). Boosting had no significant effect upon animals immunized with live RSV or by i.m. plasmid immunization.
RSV titres in nasal washes (upper respiratory tract) on day +82 are shown in Table 8 below. RSV titres in the lungs (lower respiratory tract) on day +82 are shown in Table 9 below. All of the vaccines provided protection against lung infection but under these conditions, only live virus provided total protection against upper respiratory tract infection.
The lungs from the cotton rats were examined histologically for pulmonary histopathology and the results are shown in Table 10 below. With the exception of lung sections obtained from Group 9 which were essentially free of inflammatory cells or evidence of inflammation, and those from Group 3, which exhibited the maximal pulmonary pathology seen in this study, all of the sections of lung obtained from the other groups looked familiar, i.e. scattered inflammatory cells were present in most fields, and there was some thickening of septae. These are evidence of mild inflammatory diseases. Large numbers of inflammatory cells and other evidence of inflammation were present in sections of lung from Group 3 (in which formalin-inactivated [FI] RSV vaccine was given prior to virus challenge). This result indicated that immunization with plasmid DNA expressing the RSV F protein does not result in pulmonary histopathology different from the placebo, whereas FI-RSV caused more severe pathology.
Example 6
This Example describes the determination of local lung cytokine expression profile in mice imunized with pXL2 after RSV challenge.
Balb/C mice were immunized at 0 and 6 weeks with 100 .mu.g of pXL2, prepared as described in Example 1, and challenged with RSV i.n. at 10 weeks. Control animals were immunized with FI-RSV and live RSV and challenged with RSV according to the same protocol. Four days post viral challenge, lungs were removed from immunized mice and immediately frozen in liquid nitrogen. Total RNA was prepared from lungs homogenized in TRIzol/.beta.-mercaptoethanol by chloroform extraction and isopropanol precipitation. Reverse transcriptase-polymerase chain reaction (RT-PCR) was then carried out on the RNA samples using either IL-4, IL-5 or IFN-.gamma. specific primers from Clone Tech. The amplified products were then liquid-hybridized to cytokine-specific .sup.32 P-labeled probes from Clone Tech, resolved on 5% polyacrylamide gels and quantitated by scanning of the radioactive signals in the gels. Three mouse lungs were removed from each treatment group and analyzed for lung cytokine expression for a minimum of two times. The data analyzes as follows;
As may be seen from yhe data presented in FIG. 9:
1. Immunization with live RSV intranasally (i.n.) resulted in a balanced cytokine profile (IFN-.gamma., IL-4 and IL-5), whereas that with FI-RSV intramuscularly (i.m.) resulted in a Th2 predominance (elevated IL-4 and IL-5). These results are similar to what were reported in the literature.
2. Immunization with pXL2 containing the secretary (sec.) form of FI via either the i.m. or intradermal (i.d.) route gave rise to a balanced cytokine profile similar to that with live RSV immunization.
3. The magnitude of the cytokine responses with i.m. and i.d. immunication using pXL2 expressing a secretory form of the protein in significantly higher than that with live RSV immunization.
SUMMARY OF THE DISCLOSURE
In summary of this disclosure, the present invention provides certain novel vectors containing genes encoding an RSV F proteins, methods of immunization using such vectors and methods of diagnosis using such vectors. Modifications are possible within the scope of this invention.
TABLE 1__________________________________________________________________________Immunogenic and Protective Abilities of pXL1-4 Mice via the i.m. Route Post RSV Challenge Mean Virus Mean Anti-RSV F Mean Plaque Lung Titre# No. FullyPlasmid DNA ELISA Titre(IgG)* Reduction Titre* (pfu/g lung) ProtectedImmunogen No. Mice (Log.sub.2 /100 .+-. SD) (Log.sub.4 .+-. SD) (Log.sub.10 .+-. SD) Mice**__________________________________________________________________________pXL1 8 3.00 .+-. 1.85 3.74 .+-. 0.98 0.72 .+-. 0.99 5pXL2 9 5.78 .+-. 1.72 4.82 .+-. 0.51 0.00 .+-. 0.00 9pXL3 8 3.75 .+-. 2.05 4.59 .+-. 1.16 2.77 .+-. 0.72 0pXL4 9 5.44 .+-. 1.13 5.18 .+-. 0.43 0.66 .+-. 1.00 6Placebo** 12 0.58 .+-. 2.89 0.18 .+-. 0.62 3.92 .+-. 0.27 0__________________________________________________________________________ *These sets of data from sera obtained 1 week prior to the viral challeng #Detection sensitivity of the assay was 10.sup.1.96 pfu/g lung. **The term, fully protected mice, refers to animals with no detectable RS in lungs post challenge.
TABLE 2__________________________________________________________________________Immunogenicity of pXL2 in Mice* Mean Anti-RSV F ELISA Titre Mean Plaque (Log.sub.2 /100 + SD) Reduction TitreRoute No. Mice IgG IgG1 IgG2a (Log.sub.4 .+-. SD)__________________________________________________________________________i.m 8 7.63 .+-. 0.92 4.25 .+-. 1.91 4.38 .+-. 1.92 4.18 .+-. 0.88i.d. 7 7.00 .+-. 1.00 5.00 .+-. 1.00 0.14 .+-. 0.38 3.65 .+-. 0.59Placebo 9 0.50 .+-. 0.51 0.00 .+-. 0.00 0.00 .+-. 0.00 0.18 .+-. 0.50(i.m.)__________________________________________________________________________ *These sets of data are from sera obtained 1 week prior to the viral challenge.
TABLE 3______________________________________Induction of RSV-specific CTL Following DNA Immunization* % Specific LysisRoute E:T Ratio BC BCH4______________________________________i.m. 200:1 23.3 100.6 100:1 17.0 62.4 50:1 19.9 64.1 25:1 22.3 46.4i.d. 100:1 20.9 26.1 50:1 21.7 19.1 25:1 7.1 7.0 12.5:1 2.8 2.3______________________________________ *These set of data were obtained from immunized mice immediately prior to RSV challenge.
TABLE 4______________________________________Immunoprotective Ability of pXL2 in Mice Post RSV Challenge Mean Virus Lung Titre* No. FullyRoute No. Mice (pfu/g lung) Protected Mice#______________________________________i.m. 8 0.00 .+-. 0.00 8i.d. 7 0.43 .+-. 1.13 6Placebo 9 4.30 .+-. 022 0(i.m.)______________________________________ *Detection sensitivity of the assay was 10.sup.1.69 pfu/g lung. #The term, fully protected mice, refers to animals with no detectable RSV in lungs post challenge.
TABLE 5__________________________________________________________________________RSV specific CTL included by i.m. DNA immunization are class I restrictedCTL BCH4 + anti-class IE:T Ratio BCH4 BCH4 + anti-CD4 BCH4 + anti-CD8 MHC__________________________________________________________________________100:1 52.03 54.3 39.4 8.6 50:1 44.4 47.2 27.4 6.2 25:1 28.6 26.3 14.8 1 12.5:1 18.2 15 8 -2.7__________________________________________________________________________
TABLE 6__________________________________________________________________________ RSV- Inoc. specific route Pretreatment/Group Antigen dose route Adjuvant Day 0 Day 49 Day 78 Day 88__________________________________________________________________________1 Placebo 0 I.M. Cardiotoxin Prebleed, Bleed all Challenge Harv. animals several animals; with RSV and do cotton rats boost all A2 I.N. histologic per group; except those after evaluation, prime all in group 2 bleeding all pulmonary animals virus titers, antibodies2 Live 100 I.N. None RSV CRID503 FI-RSV I.M. Alum5 pXL2 200 .mu.g I.M. None6 pXL2 200 .mu.g I.D. None7 pXL2 200 .mu.g I.M. Cardiotoxin8 pXL2 200 .mu.g I.M. Bupivacaine__________________________________________________________________________
TABLE 7(a)______________________________________RSV Serum Neutralizing Titers on Day 49 Nt. antibody titer Mean RSV- (log.sub.2 /0.05 ml) titer specific Inoc. in CR no. log2/ Stand.Group Antigen dose route 1 2 3 4 0.05 Dev.______________________________________1 Placebo 0 I.M. 4 3 2 2 2.75 1.02 Live 100 I.N. 9 9 9 9 9 0.0 RSV CRID503 FI-RSV I.M. 0 4 2 2 2.0 1.65 pXL2 200 .mu.g I.M. 9 8 8 7 8.0 0.86 pXL2 200 .mu.g I.D. 5 2 5 5 4.3 1.57 pXL2 200 .mu.g I.M. 8 8 9 9 8.5 0.68 pXL2 200 .mu.g I.M. 8 9 6 6 7.3 1.5______________________________________
TABLE 7(b)______________________________________RSV Serum Neutralizing Titers on Day 78 Nt. antibody titer Mean RSV- (log.sub.2 /0.05 ml) titer specific Inoc. in CR no. log2/ Stand.Group Antigen dose route 1 2 3 4 0.05 Dev.______________________________________1 Placebo 0 I.M. 3 2 4 Died 3.0 1.02 Live 100 I.N. 8 9 8 9 8.5 0.6 RSV CRID503 FI-RSV I.M. 8 4 6 5 5.8 1.75 pXL2 200 .mu.g I.M. 7 8 8 8 7.8 0.56 pXL2 200 .mu.g I.D. 8 6 6 Died 6.7 1.27 pXL2 200 .mu.g I.M. 8 9 9 8 8.7 0.68 pXL2 200 .mu.g I.M. 8 7 9 9 8.3 1.0______________________________________
TABLE 8__________________________________________________________________________RSV Titers in Nasal Washes on Day 82 RSV titer (log.sub.10 /0.05 ml) RSV-specific Inoc. in cotton rat no. Mean titer Stand.Group Antigen dose route 1 2 3 4 log.sub.10 /0.05 Dev.__________________________________________________________________________1 Placebo 0 I.M. 3.4 3.3 3.3 Died 3.3 0.12 Live 100 I.N. 0 0 0 0 0.0 0.0 RSV CRID503 FI-RSV I.M. 0 0 2.8 0 0.7 1.45 pXL2 200 .mu.g I.M. 3.3 2.3 3.3 2.3 2.8 0.66 pXL2 200 .mu.g I.D. N.D. N.D. N.D. Died N.D. N.D.7 pXL2 200 .mu.g I.M. 2.3 0 0 3.2 1.4 1.68 pXL2 200 .mu.g I.M. N.D. N.D. N.D. N.D. N.D. N.D.__________________________________________________________________________ N.D. = nondetermined
TABLE 9______________________________________Titers in Lungs on Day 82 RSV titer Mean RSV- (log.sub.10 /g lung) titer specific Inoc. in cotton rat no. log.sub.10 / Stand.Group Antigen dose route 1 2 3 4 0.05 Dev.______________________________________1 Placebo 0 I.M. 4.7 4.2 3.7 Died 4.2 0.52 Live 100 I.N. 0 0 0 0 0.0 0.0 RSV CRID503 FI-RSV 10.sup.5 PFU I.M. 0 0 0 0 0.0 0.05 pXL2 200 .mu.g I.M. 0 2.2 0 0 0.6 1.16 pXL2 200 .mu.g I.D. 0 2.2 2.7 3.2 2.0 N.D.7 pXL2 200 .mu.g I.M. 0 0 0 0 0.0 0.08 pXL2 200 .mu.g I.M. 0 0 0 0 0.0 N.D.______________________________________ N.D. = nondetermined
TABLE 10______________________________________Summary of Histopathology Results Seen in Sectionsof Cotton Rat Lung.Group Treatment Major Observations & Comments______________________________________1. Placebo + Scattered individual and groups of macrophages RSV and polymorphonuclear neutrophiles (PMN) in all fields. Overt thickening of septae. Occasional pyknotic cells seen. Overall: mild to moderate inflammation.2. Live RSV Isolated macrophages seen in most fields. Scattered PMN. Overall: minimal inflammation3. FI-RSV + Virtually every field contains numerous RSV mononuclear cells & PMN. Pyknotic cells and debris common. Thickened septae. Evidence of exacerbated disease.5. Plasmid + Isolated macrophages seen in most fields. RSV Occasional PMN seen. Very similar to live virus group.6. Plasmid Isolated macrophages seen in most fields. i.d. + RSV Occasional PMN seen.7. Plasmid + Isolated mononuclear cells and PMN seen in most CT + RSV fields.8. Plasmid + Scattered mononuclear cells and PMN seen in Biv + RSV most fields.9. Normal Few leukocytes evidence. Airy, open appearance. CR Lung Thin septae.______________________________________ CT = carditoxin Biv = bupivacaine
REFERENCES
1. McIntosh K., Canock, R. M. In: Fields B N, Knipe, D M, editors. Virology. New York: Raven Press: 1990: 1045-1072
2. Katz S L., In: New Vaccine Development establishing priorities. Vol. 1. Washington: National Academic Press: 1985: 397-409.
3. Wertz G W, Sullender W M., Biotechnology 1992; 20: 151-176
4. Johnson et al., J. Virol 1987, 61: 3163-3166
5. Pemberton et al., J. Gen Virol. 1987, 68: 2177-2182
6. Crowe, J. E., Vaccine 1995, 13: 415-421
7. WO 90/11092
8. WO 94/21797
9. Ulmer, Current Opinion, Invest Drugs, 1993, 2: 983-989
10. Tang et al., Nature 1992, 356: 152-154
11. Furth et al. Analytical Biochemistry, 1992, 205: 365-368
12. Pizzorno et al., J. Virol. 1988, 62: 1167-1179
13. Chapman, B. S.; Thayer, R. M.; Vincent, K. A. and Haigwood, N. L., Nucl. Acids. Res. 1991, 19: 3979-3986.
14. Green, S. Isseman, I., and Sheer, E., Nucl. Acids. Res. 1988, 16: 369
15. Breathnack, R. and Harris, B. A., Nucl. Acids Res. 1983, 11: 7119-7136
16. Graham, B. S.; Perkins M. D.; Wright, P. F. and Karzon, D. T. J. Mod. Virol. 1988 26: 153-162.
17. Nabel, G. J. 1993, Proc. Natl. Acad. Sci. USA 90: 11307-11311.
18. Du, R. P et al. 1994., Biotechnology 12: 813-818.
19. Prince, G. A. et al, 1978. Ame. J. Pathol. 93: 771-790.
20. Karasuyama & Melchers, Eur. J. Immunol. 18, 97-104, 1988
21. Wilde, David et al. 1983 J. Immunol. 131: 2178-2183.
22. Ledbetter, J. A., Rouse R., Micklem, H. 1980, J. Exp. Med. 152: 280-295.
23. Ozato Kerko et al. 1982, Transplantation 34: 113-118.
24. Davis et al., Vaccine 1994, 12:
__________________________________________________________________________# SEQUENCE LISTING- (1) GENERAL INFORMATION:- (iii) NUMBER OF SEQUENCES: 5- (2) INFORMATION FOR SEQ ID NO:1:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 1886 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:- ATGGAGTTGC CAATCCTCAA AGCAAATGCA ATTACCACAA TCCTCGCTGC AG - #TCACATTT 60- TGCTTTGCTT CTAGTCAAAA CATCACTGAA GAATTTTATC AATCAACATG CA - #GTGCAGTT 120- AGCAAAGGCT ATCTTAGTGC TCTAAGAACT GGTTGGTATA CTAGTGTTAT AA - #CTATAGAA 180- TTAAGTAATA TCAAGGAAAA TAAGTGTAAT GGAACAGATG CTAAGGTAAA AT - #TGATGAAA 240- CAAGAATTAG ATAAATATAA AAATGCTGTA ACAGAATTGC AGTTGCTCAT GC - #AAAGCACA 300- CCAGCAGCAA ACAATCGAGC CAGAAGAGAA CTACCAAGGT TTATGAATTA TA - #CACTCAAC 360- AATACCAAAA AAACCAATGT AACATTAAGC AAGAAAAGGA AAAGAAGATT TC - #TTGGTTTT 420- TTGTTAGGTG TTGGATCTGC AATCGCCAGT GGCATTGCTG TATCTAAGGT CC - #TGCACTTA 480- GAAGGAGAAG TGAACAAGAT CAAAAGTGCT CTACTATCCA CAAACAAGGC CG - #TAGTCAGC 540- TTATCAAATG GAGTTAGTGT CTTAACCAGC AAAGTGTTAG ACCTCAAAAA CT - #ATATAGAT 600- AAACAATTGT TACCTATTGT GAATAAGCAA AGCTGCAGAA TATCAAATAT AG - #AAACTGTG 660- ATAGAGTTCC AACAAAAGAA CAACAGACTA CTAGAGATTA CCAGGGAATT TA - #GTGTTAAT 720- GCAGGTGTAA CTACACCTGT AAGCACTTAC ATGTTAACTA ATAGTGAATT AT - #TGTCATTA 780- ATCAATGATA TGCCTATAAC AAATGATCAG AAAAAGTTAA TGTCCAACAA TG - #TTCAAATA 840- GTTAGACAGC AAAGTTACTC TATCATGTCC ATAATAAAAG AGGAAGTCTT AG - #CATATGTA 900- GTACAATTAC CACTATATGG TGTGATAGAT ACACCTTGTT GGAAATTACA CA - #CATCCCCT 960- CTATGTACAA CCAACACAAA AGAAGGGTCA AACATCTGTT TAACAAGAAC TG - #ACAGAGGA1020- TGGTACTGTG ACAATGCAGG ATCAGTATCT TTCTTCCCAC AAGCTGAAAC AT - #GTAAAGTT1080- CAATCGAATC GAGTATTTTG TGACACAATG AACAGTTTAA CATTACCAAG TG - #AAGTAAAT1140- CTCTGCAATG TTGACATATT CAATCCCAAA TATGATTGTA AAATTATGAC TT - #CAAAAACA1200- GATGTAAGCA GCTCCGTTAT CACATCTCTA GGAGCCATTG TGTCATGCTA TG - #GCAAAACT1260- AAATGTACAG CATCCAATAA AAATCGTGGA ATCATAAAGA CATTTTCTAA CG - #GGTGTGAT1320- TATGTATCAA ATAAAGGGGT GGACACTGTG TCTGTAGGTA ACACATTATA TT - #ATGTAAAT1380- AAGCAAGAAG GCAAAAGTCT CTATGTAAAA GGTGAACCAA TAATAAATTT CT - #ATGACCCA1440- TTAGTATTCC CCTCTGATGA ATTTGATGCA TCAATATCTC AAGTCAATGA GA - #AGATTAAC1500- CAGAGTTTAG CATTTATTCG TAAATCCGAT GAATTATTAC ATAATGTAAA TG - #CTGGTAAA1560- TCAACCACAA ATATCATGAT AACTACTATA ATTATAGTGA TTATAGTAAT AT - #TGTTATCA1620- TTAATTGCTG TTGGACTGCT CCTATACTGT AAGGCCAGAA GCACACCAGT CA - #CACTAAGC1680- AAGGATCAAC TGAGTGGTAT AAATAATATT GCATTTAGTA ACTGAATAAA AA - #TAGCACCT1740- AATCATGTTC TTACAATGGT TTACTATCTG CTCATAGACA ACCCATCTAT CA - #TTGGATTT1800- TCTTAAAATC TGAACTTCAT CGAAACTCTT ATCTATAAAC CATCTCACTT AC - #ACTATTTA1860# 1886 ATAG TTATAT- (2) INFORMATION FOR SEQ ID NO:2:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 594 amino (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:- Met Glu Leu Pro Ile Leu Lys Ala Asn Ala Il - #e Thr Thr Ile Leu Ala# 15- Ala Val Thr Phe Cys Phe Ala Ser Ser Gln As - #n Ile Thr Glu Glu Phe# 30- Tyr Gln Ser Thr Cys Ser Ala Val Ser Lys Gl - #y Tyr Leu Ser Ala Leu# 45- Arg Thr Gly Trp Tyr Thr Ser Val Ile Thr Il - #e Glu Leu Ser Asn Ile# 60- Lys Glu Asn Lys Cys Asn Gly Thr Asp Ala Ly - #s Val Lys Leu Met Lys#80- Gln Glu Leu Asp Lys Tyr Lys Asn Ala Val Th - #r Glu Leu Gln Leu Leu# 95- Met Gln Ser Thr Pro Ala Ala Asn Asn Arg Al - #a Arg Arg Glu Leu Pro# 110- Arg Phe Met Asn Tyr Thr Leu Asn Asn Thr Ly - #s Lys Thr Asn Val Thr# 125- Leu Ser Lys Lys Arg Lys Arg Arg Phe Leu Gl - #y Phe Leu Leu Gly Val# 140- Gly Ser Ala Ile Ala Ser Gly Ile Ala Val Se - #r Lys Val Leu His Leu145 1 - #50 1 - #55 1 -#60- Glu Gly Glu Val Asn Lys Ile Lys Ser Ala Le - #u Leu Ser Thr Asn Lys# 175- Ala Val Val Ser Leu Ser Asn Gly Val Ser Va - #l Leu Thr Ser Lys Val# 190- Leu Asp Leu Lys Asn Tyr Ile Asp Lys Gln Le - #u Leu Pro Ile Val Asn# 205- Lys Arg Ser Cys Arg Ile Ser Asn Ile Glu Th - #r Val Ile Glu Phe Gln# 220- His Lys Asn Asn Arg Leu Leu Glu Ile Thr Ar - #g Glu Phe Ser Val Asn225 2 - #30 2 - #35 2 -#40- Ala Gly Val Thr Thr Pro Val Ser Thr Tyr Me - #t Leu Thr Asn Ser Glu# 255- Leu Leu Ser Leu Ile Asn Asp Met Pro Ile Th - #r Asn Asp Gln Lys Lys# 270- Leu Met Ser Asn Asn Val Gln Ile Val Arg Gl - #n Gln Ser Tyr Ser Ile# 285- Met Ser Ile Ile Lys Glu Glu Val Leu Ala Ty - #r Val Val Gln Leu Pro# 300- Leu Tyr Gly Val Ile Asp Thr Pro Cys Trp Ly - #s Leu His Thr Ser Pro305 3 - #10 3 - #15 3 -#20- Leu Cys Thr Thr Asn Thr Lys Glu Gly Ser As - #n Ile Cys Leu Thr Arg# 335- Thr Asp Arg Gly Trp Tyr Cys Asp Asn Ala Gl - #y Ser Val Ser Phe Phe# 350- Pro Gln Ala Glu Thr Cys Lys Val Gln Ser As - #n Arg Val Phe Cys Asp# 365- Thr Met Asn Ser Leu Thr Leu Pro Ser Glu Va - #l Asn Leu Cys Asn Val# 380- Asp Ile Phe Asn Pro Lys Tyr Asp Cys Lys Il - #e Met Thr Ser Lys Thr385 3 - #90 3 - #95 4 -#00- Asp Val Ser Ser Ser Val Ile Thr Ser Leu Gl - #y Ala Ile Val Ser Cys# 415- Tyr Gly Lys Thr Lys Cys Thr Ala Ser Asn Ly - #s Asn Arg Gly Ile Ile# 430- Lys Thr Phe Ser Asn Gly Cys Asp Tyr Val Se - #r Asn Lys Gly Val Asp# 445- Thr Val Ser Val Gly Asn Thr Leu Tyr Tyr Va - #l Asn Lys Gln Glu Gly# 460- Lys Ser Leu Tyr Val Lys Gly Glu Pro Ile Il - #e Asn Phe Tyr Asp Pro465 4 - #70 4 - #75 4 -#80- Leu Val Phe Pro Ser Asp Glu Phe Asp Ala Se - #r Ile Ser Gln Val Asn# 495- Glu Lys Ile Asn Leu Val Phe Pro Ser Asp Gl - #u Phe Asp Ala Ser Ile# 510- Ser Gln Val Asn Glu Lys Ile Asn Gln Ser Le - #u Ala Phe Ile Arg Lys# 525- Ser Asp Glu Leu Leu His Asn Val Asn Ala Gl - #y Lys Ser Thr Thr Asn# 540- Ile Met Ile Thr Thr Ile Ile Ile Glu Ile Il - #e Val Ile Leu Leu Ser545 5 - #50 5 - #55 5 -#60- Leu Ile Ala Val Gly Leu Leu Leu Tyr Cys Ly - #s Ala Arg Ser Thr Pro# 575- Val Thr Leu Ser Lys Asp Gln Leu Ser Gly Il - #e Asn Asn Ile Ala Phe# 590- Ser Asn- (2) INFORMATION FOR SEQ ID NO:3:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 1904 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:- ATGGAGTTGC CAATCCTCAA AGCAAATGCA ATTACCACAA TCCTCGCTGC AG - #TCACATTT 60- TGCTTTGCTT CTAGTCAAAA CATCACTGAA GAATTTTATC AATCAACATG CA - #GTGCAGTT 120- AGCAAAGGCT ATCTTAGTGC TCTAAGAACT GGTTGGTATA CTAGTGTTAT AA - #CTATAGAA 180- TTAAGTAATA TCAAGGAAAA TAAGTGTAAT GGAACAGATG CTAAGGTAAA AT - #TGATGAAA 240- CAAGAATTAG ATAAATATAA AAATGCTGTA ACAGAATTGC AGTTGCTCAT GC - #AAAGCACA 300- CCAGCAGCAA ACAATCGAGC CAGAAGAGAA CTACCAAGGT TTATGAATTA TA - #CACTCAAC 360- AATACCAAAA AAACCAATGT AACATTAAGC AAGAAAAGGA AAAGAAGATT TC - #TTGGTTTT 420- TTGTTAGGTG TTGGATCTGC AATCGCCAGT GGCATTGCTG TATCTAAGGT CC - #TGCACTTA 480- GAAGGAGAAG TGAACAAGAT CAAAAGTGCT CTACTATCCA CAAACAAGGC CG - #TAGTCAGC 540- TTATCAAATG GAGTTAGTGT CTTAACCAGC AAAGTGTTAG ACCTCAAAAA CT - #ATATAGAT 600- AAACAATTGT TACCTATTGT GAATAAGCAA AGCTGCAGAA TATCAAATAT AG - #AAACTGTG 660- ATAGAGTTCC AACAAAAGAA CAACAGACTA CTAGAGATTA CCAGGGAATT TA - #GTGTTAAT 720- GCAGGTGTAA CTACACCTGT AAGCACTTAC ATGTTAACTA ATAGTGAATT AT - #TGTCATTA 780- ATCAATGATA TGCCTATAAC AAATGATCAG AAAAAGTTAA TGTCCAACAA TG - #TTCAAATA 840- GTTAGACAGC AAAGTTACTC TATCATGTCC ATAATAAAAG AGGAAGTCTT AG - #CATATGTA 900- GTACAATTAC CACTATATGG TGTGATAGAT ACACCTTGTT GGAAATTACA CA - #CATCCCCT 960- CTATGTACAA CCAACACAAA AGAAGGGTCA AACATCTGTT TAACAAGAAC TG - #ACAGAGGA1020- TGGTACTGTG ACAATGCAGG ATCAGTATCT TTCTTCCCAC AAGCTGAAAC AT - #GTAAAGTT1080- CAATCGAATC GAGTATTTTG TGACACAATG AACAGTTTAA CATTACCAAG TG - #AAGTAAAT1140- CTCTGCAATG TTGACATATT CAATCCCAAA TATGATTGTA AAATTATGAC TT - #CAAAAACA1200- GATGTAAGCA GCTCCGTTAT CACATCTCTA GGAGCCATTG TGTCATGCTA TG - #GCAAAACT1260- AAATGTACAG CATCCAATAA AAATCGTGGA ATCATAAAGA CATTTTCTAA CG - #GGTGTGAT1320- TATGTATCAA ATAAAGGGGT GGACACTGTG TCTGTAGGTA ACACATTATA TT - #ATGTAAAT1380- AAGCAAGAAG GCAAAAGTCT CTATGTAAAA GGTGAACCAA TAATAAATTT CT - #ATGACCCA1440- TTAGTATTCC CCTCTGATGA ATTTGATGCA TCAATATCTC AAGTCAATGA GA - #AGATTAAC1500- CAGAGTTTAG CATTTATTCG TAAATCCGAT GAATTATTAC ATAATGTAAA TG - #CTGGTAAA1560- TCAACCACAA ATATCATGAC TTGATAATGA GGATCCATAA CTACTATAAT TA - #TAGTGATT1620- ATAGTAATAT TGTTATCATT AATTGCTGTT GGACTGCTCC TATACTGTAA GG - #CCAGAAGC1680- ACACCAGTCA CACTAAGCAA GGATCAACTG AGTGGTATAA ATAATATTGC AT - #TTAGTAAC1740- TGAATAAAAA TAGCACCTAA TCATGTTCTT ACAATGGTTT ACTATCTGCT CA - #TAGACAAC1800- CCATCTATCA TTGGATTTTC TTAAAATCTG AACTTCATCG AAACTCTTAT CT - #ATAAACCA1860# 190 - #4GATTCCTA GTTTATAGTT ATAT- (2) INFORMATION FOR SEQ ID NO:4:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 527 amino (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:- Met Glu Leu Pro Ile Leu Lys Ala Asn Ala Il - #e Thr Thr Ile Leu Ala# 15- Ala Val Thr Phe Cys Phe Ala Ser Ser Gln As - #n Ile Thr Glu Glu Phe# 30- Tyr Gln Ser Thr Cys Ser Ala Val Ser Lys Gl - #y Tyr Leu Ser Ala Leu# 45- Arg Thr Gly Trp Tyr Thr Ser Val Ile Thr Il - #e Glu Leu Ser Asn Ile# 60- Lys Glu Asn Lys Cys Asn Gly Thr Asp Ala Ly - #s Val Lys Leu Met Lys#80- Gln Glu Leu Asp Lys Tyr Lys Asn Ala Val Th - #r Glu Leu Gln Leu Leu# 95- Met Gln Ser Thr Pro Ala Ala Asn Asn Arg Al - #a Arg Arg Glu Leu Pro# 110- Arg Phe Met Asn Tyr Thr Leu Asn Asn Thr Ly - #s Lys Thr Asn Val Thr# 125- Leu Ser Lys Lys Arg Lys Arg Arg Phe Leu Gl - #y Phe Leu Leu Gly Val# 140- Gly Ser Ala Ile Ala Ser Gly Ile Ala Val Se - #r Lys Val Leu His Leu145 1 - #50 1 - #55 1 -#60- Glu Gly Glu Val Asn Lys Ile Lys Ser Ala Le - #u Leu Ser Thr Asn Lys# 175- Ala Val Val Ser Leu Ser Asn Gly Val Ser Va - #l Leu Thr Ser Lys Val# 190- Leu Asp Leu Lys Asn Tyr Ile Asp Lys Gln Le - #u Leu Pro Ile Val Asn# 205- Lys Gln Ser Cys Arg Ile Ser Asn Ile Glu Th - #r Val Ile Glu Phe Gln# 220- His Lys Asn Asn Arg Leu Leu Glu Ile Thr Ar - #g Glu Phe Ser Val Asn225 2 - #30 2 - #35 2 -#40- Ala Gly Val Thr Thr Pro Val Ser Thr Tyr Me - #t Leu Thr Asn Ser Glu# 255- Leu Leu Ser Leu Ile Asn Asp Met Pro Ile Th - #r Asn Asp Gln Lys Lys# 270- Leu Met Ser Asn Asn Val Gln Ile Val Arg Gl - #n Gln Ser Tyr Ser Ile# 285- Met Ser Ile Ile Lys Glu Glu Val Leu Ala Ty - #r Val Val Gln Leu Pro# 300- Leu Tyr Gly Val Ile Asp Thr Pro Cys Trp Ly - #s Leu His Thr Ser Pro305 3 - #10 3 - #15 3 -#20- Leu Cys Thr Thr Asn Thr Lys Glu Gly Ser As - #n Ile Cys Leu Thr Arg# 335- Thr Asp Arg Gly Trp Tyr Cys Asp Asn Ala Gl - #y Ser Val Ser Phe Phe# 350- Pro Gln Ala Glu Thr Cys Lys Val Gln Ser As - #n Arg Val Phe Cys Asp# 365- Thr Met Asn Ser Leu Thr Leu Pro Ser Glu Va - #l Asn Leu Cys Asn Val# 380- Asp Ile Phe Asn Pro Lys Tyr Asp Cys Lys Il - #e Met Thr Ser Lys Thr385 3 - #90 3 - #95 4 -#00- Asp Val Ser Ser Ser Val Ile Thr Ser Leu Gl - #y Ala Ile Val Ser Cys# 415- Tyr Gly Lys Thr Lys Cys Thr Ala Ser Asn Ly - #s Asn Arg Gly Ile Ile# 430- Lys Thr Phe Ser Asn Gly Cys Asp Tyr Val Se - #r Asn Lys Gly Val Asp# 445- Thr Val Ser Val Gly Asn Thr Leu Tyr Tyr Va - #l Asn Lys Gln Glu Gly# 460- Lys Ser Leu Tyr Val Lys Gly Glu Pro Ile Il - #e Asn Phe Tyr Asp Pro465 4 - #70 4 - #75 4 -#80- Leu Val Phe Pro Ser Asp Glu Phe Asp Ala Se - #r Ile Ser Gln Val Asn# 495- Glu Lys Ile Asn Gln Ser Leu Ala Phe Ile Ar - #g Lys Ser Asp Glu Leu# 510- Leu His Asn Val Asn Ala Gly Lys Ser Thr Th - #r Asn Ile Met Thr# 525- (2) INFORMATION FOR SEQ ID NO:5:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 573 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:- GTGAGTTTGG GGACCCTTGA TTGTTCTTTC TTTTTCGCTA TTGTAAAATT CA - #TGTTATAT 60- GGAGGGGGCA AAGTTTTCAG GGTGTTGTTT AGAATGGGAA GATGTCCCTT GT - #ATCACCAT 120- GGACCCTCAT GATAATTTTG TTTCTTTCAC TTTCTACTCT GTTGACAACC AT - #TGTCTCCT 180- CTTATTTTCT TTTCATTTTC TGTAACTTTT TCGTTAAACT TTAGCTTGCA TT - #TGTAACGA 240- ATTTTTAAAT TCACTTTTGT TTATTTGTCA GATTGTAAGT ACTTTCTCTA AT - #CACTTTTT 300- TTTCAAGGCA ATCAGGGTAT ATTATATTGT ACTTCAGCAC AGTTTTAGAG AA - #CAATTGTT 360- ATAATTAAAT GATAAGGTAG AATATTTCTG CATATAAATT CTGGCTGGCG TG - #GAAATATT 420- CTTATTGGTA GAAACAACTA CATCCTGGTC ATCATCCTGC CTTTCTCTTT AT - #GGTTACAA 480- TGATATACAC TGTTTGAGAT GAGGATAAAA TACTCTGAGT CCAAACCGGG CC - #CCTCTGCT 540# 573 TCTT CTTTTTCCTA CAG__________________________________________________________________________

Number	Name	Date	Kind
5149650	Wertz et al.	Sep 1992
5589466	Felgner et al.	Dec 1996

Number	Date	Country
WO 9011092	Oct 1990	WOX
WO 9207940	May 1992	WOX
WO 9322310	Oct 1993	WOX
WO 9421797	Sep 1994	WOX

	Number	Date	Country
Parent	659939	Jun 1996
Parent	476397	Jun 1995

Nucleic acid respiratory syncytial virus vaccines

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

US Classifications

Field of Search

US

International Classifications

Abstract

Description

Claims

REFERENCE TO RELATED APPLICATION

US Referenced Citations (2)

Foreign Referenced Citations (4)

Non-Patent Literature Citations (21)

Continuation in Parts (2)